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Abstract
Background: N-acetyltransferases (NAT) and glutathione S-transferases (GST) are involved in
the metabolism of several ubiquitous chemical substances leading to the activation and
detoxification of carcinogenic heterocyclic and aromatic amines. Since polymorphisms within these
genes are described to influence the metabolism of ubiquitous chemicals, we conducted the present
study to determine if individuals with self-reported chemical-related sensitivity differed from
controls without self-reported chemical-related sensitivity with regard to the distribution of
genotype frequencies of NAT2, GSTM1, GSTT1, and GSTP1 polymorphisms.
Methods: Out of 800 subjects who answered a questionnaire of ten items with regard to their
severity of chemical sensitivity 521 unrelated individuals agreed to participate in the study.
Subsequently, genetic variants of the NAT2, GSTM1, GSTT1, and GSTP1 genes were analyzed.
Results:  The results show significant differences between individuals with and without self-
reported chemical-related sensitivity with regard to the distribution of NAT2, GSTM1, and GSTT1
gene variants. Cases with self-reported chemical-related sensitivity were significantly more
frequently NAT2 slow acetylators (controlled OR = 1.81, 95% CI = 1.27–2.59, P = 0.001). GSTM1
and GSTT1 genes were significantly more often homozygously deleted in those individuals reporting
sensitivity to chemicals compared to controls (GSTM1: controlled OR 2.08, 95% CI = 1.46–2.96, P
= 0.0001; GSTT1: controlled OR = 2.80, 95% CI = 1.65–4.75, P = 0.0001). Effects for GSTP1 gene
variants were observed in conjunction with GSTM1, GSTT1 and NAT2 gene.
Conclusion: The results from our study population show that individuals being slow acetylators
and/or harbouring a homozygous GSTM1  and/or  GSTT1  deletion reported chemical-related
hypersensitivity more frequently.
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Background
Hypersensitivity against common environmental chemi-
cals belongs to a complex of symptoms which are fre-
quently reported by individuals suffering from a
condition, variously referred to as multiple chemical sen-
sitivity (MCS), chronic fatigue syndrome (CFS), or idio-
pathic environmental intolerance (IEI). In a position
paper from 1999 the American College of Occupational
and Environmental Medicine (ACOEM) stated that these
terms refer to recurrent non-specific symptoms from mul-
tiple organ systems that the patients believe are provoked
by exposure to low concentrations of chemical agents [1].
According to Cullen, the following criteria summarize the
symptoms of these hypersensitivities: they are acquired
after a specific health event in association with an envi-
ronmental exposure, symptoms involve more than one
organ system, symptoms recur and abate in response to
predictable stimuli, symptoms are elicited by exposure to
chemicals of diverse classes and modes of action, symp-
toms occur in response to very low levels of chemicals,
and no widely available test of organ system function can
explain the symptoms [2]. Nevertheless, the reasons for
suffering from hypersensitivities to common environ-
mental chemicals are unknown and it is supposed that
genetic variants may influence individual response. In a
recently published case-control study it was reported that
polymorphisms of drug-metabolizing enzymes predis-
posed individuals to multiple chemical sensitivity [3].
However, since it is whether gene variants of drug-metab-
olizing enzymes are involved in the pathogenesis of idio-
pathic environmental intolerance, further data are
necessary to characterise patients suffering from chemical
hypersensitivity.
Glutathione S-transferases and N-acetyltransferases are
biotransformation enzymes which are involved in the
metabolism of ubiquitous chemical substances. Glutath-
ione S-transferases catalyse glutathione-mediated reduc-
tion of exogenous and endogenous electrophiles. These
enzymes have broad and overlapping substrate specifici-
ties and it has been hypothesized that allelic variants are
associated with less effective detoxification of common
chemical substances [4-6]. Analysis of DNA adducts and
cytogenetic endpoints have indicated an increased suscep-
tibility of glutathione S-transferase M1 and/or T1
(GSTM1, GSTT1) null genotype to genotoxicity of com-
mon low-dose chemicals [7-9]. For example, some chem-
icals cannot be conjugated by glutathione due to the
deletion of GSTM1 gene. As a consequence of missing glu-
tathione conjugation, chromosomal aberrations and sis-
ter chromatide exchange may be induced in lymphocytes
exposed to a low dose of monoepoxybutene [10]. Glu-
tathione S-transferases are involved in gene-environment
interactions, may modify the individual predisposition to
various diseases and were shown to influence the treat-
ment response to drugs such as glucocorticoids and
alkylating agents [11-16].
N-acetyltransferases are involved in the metabolism of
arylamine and heterocyclic amines that are produced in
industry, and found in cigarette smoke as well as the
human diet. Bioactivation of arylamines and heterocyclic
amines by N-hydroxylation is catalysed predominantly in
the liver in various species and detoxification of
arylamines is catalysed via N-acetylation [17]. The clear-
ance of low-dose carcinogens have been described to be
decreased in the genetically based slow-acetylator pheno-
type [18]. N-acetyltransferase 2 (NAT2) functional differ-
ences are explained by genetic variants within this
intronless gene leading to the slow or rapid acetylator
phenotype. Slow acetylators appear with a frequency of
50–60% in Caucasians. In a meta-analysis of 42 studies
NAT2 has been identified to modulate susceptibility to
colorectal cancer [19,20]. Other studies reported that
acetylation by NAT2 has an impact on drug response [21-
23]. Furthermore, it was shown to be a risk factor for indi-
vidual susceptibility to various cancers like bladder cancer
[24,25] and non-cancer diseases [26-28].
The lack of a generally accepted case definition for chem-
ical hypersensitivity has delayed progress in this area.
Miller & Prihoda developed a questionnaire called EESI
(Environmental Exposure and Sensitivity Inventory) with
self-rating scales to assess Symptom Severity, Chemical
Inhalant Intolerances, Life Impact and Other Intolerances
(e.g., foods, medications, alcohol) [29]. A sensitivity of
92% and specificity of 95% was achieved using scales of
the questionnaire to differentiate cases from controls. Fur-
ther investigation from an Asian population confirmed
that findings from scales can be used for surveys and for
diagnostic assessment of patients with idiopathic environ-
mental intolerance [30].
This study was designed to evaluate chemical-related sen-
sitivity to common ubiquitous substances in subjects with
and without self-reported sensitivity and to analyze these
findings in association with genetic variants of drug-
metabolizing enzymes.
Methods
Study design
A modified questionnaire was used to collect information
on individual chemical-related sensitivity from voluntary
subjects (Table 1). This questionnaire included ten items
associated with different ubiquitous chemicals. To assess
reliability, the questionnaire was administered twice in 20
randomly selected volunteers, with the second adminis-
tration occurring 7 days after the initial administration.
The scores of the questionnaire of these subjects corre-
lated at both dates. All 20 volunteers were identified asEnvironmental Health 2007, 6:6 http://www.ehjournal.net/content/6/1/6
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control or case due to a score of 10–20 or 21–30 points at
both surveys. To assess validity, the questionnaire was
compared to the part of the environmental exposure and
sensitivity inventory (EESI, [29]) which asked for the
same chemicals in our questionnaire. Our questionnaire
used a rating scale of 1–3 in contrast to the rating scale of
0–10 in the EESI questionnaire. This standardized
approach for measuring chemical intolerances was tested
in 20 randomly selected volunteers. The scores of our
questionnaire were in accordance with the scores of EESI.
Subjects achieving a score of 10–20 or 21–30 points using
our questionnaire corresponded to scores of 0–50 or 51–
100 in the EESI questionnaire.
In total, 800 randomly selected volunteers from a general
practice in Hamburg, Germany, were asked to answer our
questionnaire between September 1998 and April 2003.
Out of these 800 subjects, 521 individuals agreed to par-
ticipate in the study. Participants were instructed to use a
rating scale that best corresponded to the severity of their
sensitivity by checking a score of 1 to 3 points (not at all a
problem, moderate symptoms, disabling symptoms) was
to be marked by the subjects. A minimum of ten (all
chemicals not a problem) and a maximum of 30 points
(all chemicals disabling symptoms) were achievable. Par-
ticipants were patients of a general practice with or with-
out any disease for routine examination. None of the
subjects was recruited according to the definition of Cul-
len [2]. Therefore, participants of our study were not
assessed to one of the seven items which were proposed
by Cullen for patients that suffer from multiple chemical
sensitivity (MCS). Nevertheless, we can not exclude that
patients with symptoms defined by Cullen are random
participants of our study.
Subjects were divided into two groups according to the
score achieved. Individuals with a score of > 20 were
defined as sensitive to common chemicals (cases) while
individuals with moderate or no symptoms were classi-
fied as non-sensitive (controls, ≤ 20 scores). The obtained
scores were described as 'chemical-related sensitivity'
scores (CRS). All individuals were of Caucasian origin
with Caucasian parents living in the area of North Ger-
many. The number of individuals born in the area of
North Germany was equally distributed in cases and con-
trols. The study conformed to good clinical practice guide-
lines and was carried out according to the guidelines of
the Declaration of Helsinki. Written informed consent
was obtained from each subject and the study was
approved by the local ethic commission (Hannover, Ger-
many). Participants were excluded from the study group
of 800 individuals if they suffered from severe or chronic
diseases like diabetes mellitus type I or II (n = 51) or onco-
logical diseases (n = 13). Exclusion criteria were misusage
of drugs or alcohol (n = 80) or misused exposition to any
chemical (n = 25) which was assessed by asking the indi-
vidual prior to fill the questionnaire or if they refused to
participate into genotyping (n = 110). None of the 521
subjects refused participation in the study after genotyp-
ing.
Genotyping
DNA was isolated from EDTA blood as described by Lahiri
and Nürnberger or using the QIAamp DNA Blood Mini
Kit [31]. After DNA extraction, the NAT2 gene was ampli-
fied as previously described [32]. The single nucleotide
polymorphisms (SNPs) nt 481, nt 590, and nt 857 of the
N-acetyltransferase 2 gene were analysed using RFLP/PCR
or real-time PCR. The NAT2 nomenclature of the
Arylamine N-Acetyltransferase Nomenclature Committee
was used [33]. The genetic variants analysed in this study
lead to a 4-allele model of the NAT2 gene which can pre-
dict the acetylator phenotype with an accuracy of more
than 95% for slow and rapid acetylation [34]. Since the
number of homozygous rapid acetylators (NAT2*4/*4)
are small in Caucasians (approx. 5%) in contrast to Asian
populations we did not differentiate between hetero-
zygous and homozygous rapid acetylators.
Table 1: Questionnaire of ten common chemicals.
Please indicate whether or not these odors or exposures would make you feel sick... Not at all a 
problem
Moderate 
symptoms
Disabling 
symptoms
Diesel or gas engine exhaust
Tobacco smoke
Insecticide
Gasoline
Paint or paint thinner
Cleaning products such as disinfectants, bleach, bathroom cleaners or floor cleaners
Certain perfumes, air fresheners or other fragances
Fresh tar or asphalt
Nail polish, nail polish remover, or hair spray
New furnishings such as new carpeting, a new soft plastic shower curtain or the interior of a new carEnvironmental Health 2007, 6:6 http://www.ehjournal.net/content/6/1/6
Page 4 of 10
(page number not for citation purposes)
The detection of homozygous deletions of the GSTM1
and/or GSTT1 was performed by multiplex-PCR as previ-
ously described [32]. Two gene variants within the GSTP1
gene leading to an amino acid exchange in exon 5 (I105V)
and exon 6 (A114V) were analysed by means of PCR/
RFLP. DNA (100 ng) was amplified (HotStarTaq, Qiagen,
Germany) by 94°C (30 sec), 60°C (30 sec), 72°C (30 sec)
and a final extension step at 72°C for 10 min. Primers
were synthesised as described in the literature [35,36].
PCR fragments (each 25 μl) were digested with BsmA (5
units; I105V) and Cac8 (1,6 units; A114V) as described by
the manufacturer (New England Biolabs, US). Electro-
phoresis was performed using a DNA LabChip system
(Agilent Technologies, US). This protocol permits the
identification of the GSTP1 alleles GSTP1*A (Ile105/
Ala114), GSTP1*B (Val105/Ala114), GSTP1*C (Val105/
Val114) and GSTP1*D (Ile105/Val114) according to Ali-
Osman et al. [37].
Statistical analysis
For descriptive purposes, frequencies of characteristics
and common factors potentially affecting self-reported
chemical sensitivity were obtained at the beginning of the
analysis. To investigate the interrelationships between
such factors, self-reported chemical sensitivity scores and
NAT2,  GSTM1,  GSTT1, and GSTP1  genotypes, contin-
gency tables and Spearman correlation coefficients were
computed. The association of chemical-related sensitivity
scores with NAT2, GSTM1, GSTT1, and GSTP1 genotypes
was examined by use of univariate and multivariate
unconditional logistic regression analysis to calculate
odds ratios (OR) and their 95% confidence intervals (CI).
P values of < 0.05 were considered statistically significant.
Genotypes were used as categorical variables in these anal-
yses. The SPSS statistical package (SPSS Inc., Chicago, IL)
was used for computerized calculations.
Results
In this study we applied a questionnaire asking for chem-
ical-related sensitivity to ten common substances (Table
1) which was answered by 521 individuals seeking care at
a single general medical practice between September 1998
and April 2003. This group of 521 individuals was then
categorized in two groups at the median self-reported
chemical-related sensitivity score (≤ 20 and > 20; see table
2). When investigating the association of factors poten-
tially affecting the interrelationship of self-reported chem-
ical sensitivity score and NAT2,  GSTM1,  GSTT1, and
GSTP1 genotypes, we observed slight differences in the
distribution of gender and smoking status between the
two categories of self-reported chemical sensitivity scores.
Individuals in the lower category with scores of ≤ 20
tended to show a smaller percentage of females and more
current smokers. Age was differentially distributed
between the two categories with no significant differences
comparing the median age between the two groups (table
2).
Table 3 shows the distribution of NAT2, GSTM1, GSTT1,
and GSTP1  genotypes by self-reported chemical-related
sensitivity score (≤ 20 vs. > 20). The genotype distribu-
tions of each gene in the entire sample did not differ sig-
nificantly from those predicted by the Hardy-Weinberg
law. Table 3 also shows the association of NAT2, GSTM1,
GSTT1, and GSTP1 genotypes with chemical-related sensi-
tivity scores (≤ 20 vs. > 20). The risk of a score > 20 was
significantly higher for study subjects carrying low-activity
NAT2  alleles or showing homozygous deletions of
GSTM1  and/or  GSTT1  when compared to individuals
with genotypes conferring higher enzyme activity. These
results did not change in multivariate analyses when con-
trolling for gender, age and smoking status. After stratifi-
cation by gender the NAT2 results showed an increased
odds ratio in women with a slow acetylator status in con-
trast to male subjects (Table 4). For GSTP1, no differences
in the distribution of genotypes in the two categories were
observed (table 3), neither in uni- nor in multivariate
analysis.
When we compared the number of gene variants between
individuals with a chemical-related sensitivity score ≤ 20
vs. those with scores > 20, we observed an increasing
chemical-related sensitivity score in association with the
number of variant genotypes (Figure 1). Subjects with
three putative risk genotypes (GSTM1  deletion and/or
GSTP1 variant genotypes and/or GSTT1 deletion and/or
NAT2 slow acetylator) harbour a significantly increased
risk to report from chemical-related hypersensitivity than
individuals without a gene variant. Interestingly, calcula-
tion of GSTP1  variant genotypes in combination with
other variant genotypes showed an effect in regard to an
additionnally increased CRS score (Figure 1).
Discussion
In a meta-analysis using the database of the International
Project on Genetic Susceptibility to Environmental Car-
cinogens (GSEC) the allele and genotype frequencies for
many of the more commonly studied metabolic genes
(CYP1A1, CYP2E1, CYP2D6, GSTM1, GSTT1, NAT2,
GSTP1, and EPHX1) in the human population have been
determined [38]. If we take together the genotype fre-
quencies of cases and controls of our study we observed
the same genotype frequency of GSTM1, GSTP1, GSTT1,
and NAT2 as reported by [38]. These results indicate that
the genotype frequencies in our study population did not
deviate from published data and that the distribution of
genotypes was not influenced by our study design. If indi-
viduals were divided in cases and controls using the scores
from self-reported chemical-related sensitivity, we
observed significant differences for distribution of geno-Environmental Health 2007, 6:6 http://www.ehjournal.net/content/6/1/6
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type frequencies of GSTM1, GSTT1 and the NAT2 gene.
Our results suggest that individuals with a deletion of
GSTM1 or GSTT1 or slow acetyltators are at higher risk for
developing self-reported chemical-related sensitivity.
The glutathione S-transferases are known to inactivate
exogenous chemicals by glutathione conjugation. It is
suggested that individuals with decreased glutathione
conjugation are more prone to be unable to metabolize
chemicals in the environment. It is also possible that both
enzymes, GSTM1 and GSTT1, are metabolizing endog-
enous substrates less effectively due to gene deletion lead-
ing to an increased level of the parent compound.
Although we did not differentiate between heterozygous
and homozygous carriers of GSTM1 or GSTT1 by means
of PCR, each of the homozygous deletions alone sup-
ported a direct role of the enzyme being associated with
increased risk to self-reported chemical-related sensitivity.
According to other authors, glutathione S-transferases
play an important role in the detoxification of toxic chem-
icals. Nakajima et al. analysed GSTM1 genotype and total
GST activity using 1-chloro-2,4-dinitrobenzene as a sub-
strate and observed a greater GST activity in patients with
the GSTM1 gene [39]. An interaction between GSTM1
genotypes and benzo [a]pyrene DNA adducts through air
pollution in urban and rural areas was investigated in 120
healthy non-smoking residents indicating that the dele-
tion of the GSTM1 gene may be an important step in the
early onset of diseases [40]. It is also consistent with cases
of our study group that homozygous GSTM1 deletion
may be associated with an enhanced chemical-related sen-
sitivity.
For GSTT1, there was a significant difference (OR: 2.80; p
< 0.0001) between cases and controls in genotype fre-
quency. This over-representation of cases with a
homozygous GSTT1 deletion suggests that the GSTT1
enzyme plays an important role in glutathione conjuga-
tion of exogenous and/or endogenous substrates. This
might result in cellular damage leading to an increased
sensitivity if exposed to environmental chemicals. As
described by other publications, individuals with a
homozygous deletion of GSTT1 lack the possibility for
enzymatic conjugation of environmental carcinogens
such as 1,3-butadiene, ethylene oxide, epoxybutanes,
methyl bromide, dichloromethane, and monohalometh-
anes [5-7]. In vitro experiments showed that the GSTT1
null genotype increased the sensitivity for sister chromatid
exchange after exposure to diepoxybutane [41]. Genotoxic
effects have been observed after exposure of lymphocytes
to styrene or the metabolite styrene-7,8-oxide using a sis-
ter chromatid exchange assay [42,43]. These findings pro-
vide evidence that frequently used chemicals increase the
susceptibility to develop chemical-related diseases. In
addition, the GSTT1 null genotype conferred a 2.8-fold
reduction in risk of relapse in childhood acute lymphob-
Table 2: Characteristics of the entire study population and by CRS score (CRS ≤ 20; CRS > 20) in 521 subjects.
All subjects n = 521 CRS≤ 20 n = 248 CRS > 20 n = 273 Pa
Number of subjects (%)
Gender
Male 223 (42.8) 115 (46.4) 108 (39.6)
Female 298 (57.2) 133 (53.6) 165 (60.4) 0.13
Age (years)
0–9 2 (0.4) 2 (0.8) -
10–19 17 (3.3) 13 (5.2) 4 (1.5)
20–29 32 (6.1) 21 (8.5) 11 (4.0)
30–39 88 (16.9) 44 (17.7) 44 (16.1)
40–49 105 (20.2) 42 (16.9) 63 (23.1)
50–59 148 (28.4) 56 (22.6) 92 (33.7)
60–69 90 (17.3) 45 (18.1) 45 (16.5)
70–79 31 (6.0) 18 (7.3) 13 (4.8)
80–89 6 (1.2) 5 (2.0) 1 (0.4)
90–99 2 (0.4) 2 (0.8) - 0.001#
Median age (range) 51.2 (7.5–98.0) 51.4 (13.9–84.6) 50.2 (7.5–98.0) 0.44
Smoking
current 165 (31.7) 90 (36.3) 75 (27.5)
former 23 (4.4) 11 (4.4) 12 (4.4)
never 333 (63.9) 147 (59.3) 186 (68.1) 0.09
#calculated by using Kolmogorov-Smirnov testEnvironmental Health 2007, 6:6 http://www.ehjournal.net/content/6/1/6
Page 6 of 10
(page number not for citation purposes)
lastic leukemia indicating a more cytotoxic effect of chem-
otherapy [16]. In our study, we observed an increased
chemical-related sensitivity in subjects with homozygous
GSTT1 deletion leading to the assumption that the dele-
tion of this gene augments the susceptibility to environ-
mental chemicals.
No case-control differences were observed in genotype or
allelic frequencies of GSTP1. Common chemicals are
metabolized by GSTP1 and have been associated with risk
to develop diseases like non-Hodgkin's lymphoma, hepa-
tocellular and prostate carcinoma, as well as Alzheimer.
Furthermore, Gilliland et al. reported a diesel exhaust par-
ticle enhancement in patients with GSTP1 Ile105Ile geno-
type [44]. However, we cannot exclude GSTP1 as a
candidate gene for chemical-induced sensitivity since we
did not analyse for promotor hypermethylation. Interest-
ingly, the homoyzgous GSTP1*D/*D and the hetero-
zygous GSTP1*C/*D genotype were not observed in cases
and controls.
The GST enzymes, GSTM1, GSTT1 and GSTP1, are
described to protect cells and organs from oxidative stress
by conjugation of glutathione [46]. They detoxify a variety
of electrophilic compounds, including oxidized lipid,
DNA and catechol products generated by reactive oxygen
species-induced damage to intracellular molecules. There-
fore we can conclude that the deletion of GSTM1 and/or
GSTT1 gene in individuals with chemical-related sensitiv-
ity lead to the loss of protection against oxidative stress. At
the endpoint of this cellular process, individuals with
chemical-related sensitivity may be more prone to symp-
toms like muscular pain, cardiovascular diseases, gas-
trointestinal disorders and several other symptoms that
are described by patients suffering from MCS [2,3].
The results of our study show that cases were more fre-
quently slow acetylators. The over-representation of the
homozygous rapid acetylator genotype (NAT2*4/*4)
reported by the study of McKeown-Eyssen et al. has been
associated with the role of NAT2 in bioactivating
Table 3: Association of the CRS score (CRS ≤ 20; CRS > 20) with NAT2, GSTM1, GSTP1 and GSTT1.
Gene Genotype CRS ≤ 20 n (%) CRS > 20 n (%) Univariate odds ratio (95% CIa) Multivariateb odds ratio (95% CI) Pc
n = 248 n = 273
NAT2 fast *4/*4 15 (6.0) 13 (4.8) 1.00d 1.00d
*4/*5 68 (27.4) 49 (17.9) 0.83 (0.36–1.90) 0.83 (0.36–1.92) 0.668
*4/*6 39 (15.7) 34 (12.5) 1.01 (0.42–2.41) 0.97 (0.40–2.33) 0.937
*4/*7 3 (1.2) 5 (1.8) 1.92 (0.38–9.65) 1.88 (0.37–9.47) 0.446
NAT2 slow *5/*5 49 (19.8) 61 (22.3) 1.44 (0.62–3.30) 1.51 (0.65–3.50) 0.339
*5/*6 56 (22.6) 74 (27.1) 1.52 (0.67–3.46) 1.57 (0.69–3.60) 0.286
*5/*7 4 (1.6) 5 (1.8) 1.44 (0.32–6.53) 1.46 (0.32–6.71) 0.627
*6/*6 14 (5.6) 31 (11.4) 2.55 (0.96–6.77) 2.56 (0.95–6.89) 0.062
*6/*7 - 1 (0.4) n.c.e n.c.e -
*7/*7 - - - - -
NAT2 fast all 125 (50.4) 101 (37.0) 1.00d 1.00d
NAT2 slow all 123 (49.6) 172 (63.0) 1.73 (1.22–2.46) 1.81 (1.27–2.59) 0.001
GSTM1 *1/*1 or *0/*1 143 (57.7) 109 (39.9) 1.00d 1.00d
*0/*0 105 (42.3) 164 (60.1) 2.05 (1.44–2.91) 2.08 (1.46–2.96) 0.0001
GSTT1 *1/*1 or *0/*1 226 (91.1) 214 (78.4) 1.00d 1.00d
*0/*0 22 (8.9) 59 (21.6) 2.83 (1.68–4.78) 2.80 (1.65–4.75) 0.0001
GSTP1 *A/*A 106 (42.7) 117 (42.9) 1.00d 1.00d
*A/*B 82 (33.1) 101 (37.0) 1.12 (0.75–1.65)e 1.17 (0.79–1.75)e 0.433
*A/*C or *B/*D 29 (11.7) 20 (7.3)
*A/*D 2 (0.8) 5 (1.8)
*B/*B 21 (8.5) 22 (8.1)
*B/*C 5 (2.0) 7 (2.6)
*C/*C 3 (1.2) 1 (0.4)
*C/*D - -
*D/*D - -
all except *A/*A 142 (57.3) 156 (57.1) 1.00 (0.70–1.41) 1.04 (0.73–1.48) 0.83
aconfidence interval; badjusted for age (continous); gender; smoking (current; former; never); cmultivariate logistic regression; dreference category; 
ecomprising all variant GSTP1 genotypes.Environmental Health 2007, 6:6 http://www.ehjournal.net/content/6/1/6
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arylamines to protein-binding metabolites [3]. The results
of our study indicate that inactivation of arylamines
through N-acetylation is an important mechanism.
Wormhoudt et al. described that the slow acetylator gen-
otype NAT2*6/*6 leads to a significant decreased acetyla-
tion capacity (11% vs. 100% compared to NAT2*4/*4)
[45]. This genotype was observed more frequent in cases
compared to controls in our study. Nevertheless, our
results are not in contrast to the study of McKeown-Eyssen
et al. since our study subjects were identified by a ques-
tionnaire asking for chemical hypersensitivity and not for
symptoms of MCS. McKeown-Eyssen et al. drew up
female patients from a larger study where participants
were identified by symptoms described in six previously
published MCS case definitions [2,3]. We also calculated
our study subjects stratified by gender and observed that
female slow acetylators were more prone to report chem-
ical-related sensitivity than male subjects. We cannot
exclude that some individuals of our study fit into one of
the published MCS case definitions but since the results of
the MCS study of McKeown-Eyssen et al. are symptoms-
related, the results of our study are not comparable with
those from McKeown-Eyssen's study. In addition, since
the area of McKeown-Eyssen's study corresponds to the
area where we did our study in regard to industrialisation,
we suppose that slow acetylation and lack of glutathione
conjugation is an important step to increase chemical-
related sensitivity.
Conclusion
In conclusion, we observed that individuals with self-
reported chemical-related sensitivity were more frequent
carriers of genetic variants of GSTM1, GSTT1 and NAT2.
We believe that our results reflect the gene-environment
associations of increased chemical-related sensitivity in
individuals suffering from diseases like MCS, IEI or CFS
but have to be reproduced in further studies to prove our
observations.
Table 4: Association of the CRS score (CRS ≤ 20; CRS > 20) with NAT2 genotype stratified by gender.
Gene Genotype CRS ≤ 20 n (%) CRS > 20 n (%) Univariate odds ratio (95% CIa) Multivariateb odds ratio (95% CI) Pc
Females (n = 298)
NAT2 fast *4/*4 9 (6.8) 7 (4.2) 1.00d 1.00d
*4/*5 40 (30.1) 30 (18.2) 0.96 (0.32–2.88) 0.97 (0.32–2.91) 0.958
*4/*6 24 (18.0) 22 (13.3) 1.18 (0.38–3.70) 1.18 (0.37–3.70) 0.780
*4/*7 2 (1.5) 3 (1.8) 1.93 (0.25–14.89) 2.01 (0.26–15.56) 0.505
NAT2 slow *5/*5 19 (14.3) 35 (21.2) 2.37 (0.76–7.37) 2.38 (0.76–7.42) 0.136
*5/*6 29 (21.8) 43 (26.1) 1.91 (0.64–5.69) 1.93 (0.64–5.77) 0.241
*5/*7 2 (1.5) 3 (1.8) 1.93 (0.25–14.88) 1.92 (0.25–14.84) 0.533
*6/*6 8 (6.0) 21 (12.7) 3.38 (0.94–12.14) 3.44 (0.95–12.44) 0.059
*6/*7 - 1 (0.6) n.c.e n.c.e -
*7/*7 - - - - -
NAT2 fast all 75 (56.4) 62 (37.6) 1.00d 1.00d
NAT2 slow all 58 (43.6) 103 (62.4) 2.15 (1.35–3.42) 2.16 (1.35–3.44) 0.001
Males (n = 223)
NAT2 fast *4/*4 6 (5.2) 6 (5.6) 1.00d 1.00d
*4/*5 28 (24.3) 19 (17.6) 0.68 (0.19–2.42) 0.68 (0.19–2.52) 0.568
*4/*6 15 (13.0) 12 (11.1) 0.80 (0.20–3.13) 0.73 (0.18–2.95) 0.662
*4/*7 1 (0.9) 2 (1.9) 2.00 (0.14–28.41) 1.45 (0.10–21.03) 0.786
NAT2 slow *5/*5 30 (26.1) 26 (24.1) 0.87 (0.25–3.02) 0.93 (0.26–3.34) 0.905
*5/*6 27 (23.5) 31 (28.7) 1.15 (0.33–3.98) 1.18 (0.33–4.24) 0.798
*5/*7 2 (1.7) 2 (1.9) 1.00 (0.10–9.61) 0.95 (0.09–9.65) 0.963
*6/*6 6 (5.2) 10 (9.3) 1.67 (0.37–7.61) 1.61 (0.33–7.76) 0.555
*6/*7 - - - - -
*7/*7 - - - - -
NAT2 fast all 50 (43.5) 39 (36.1) 1.00d 1.00d
NAT2 slow all 65 (56.5) 69 (63.9) 1.36 (0.79–2.33) 1.45 (0.82–2.56) 0.199Environmental Health 2007, 6:6 http://www.ehjournal.net/content/6/1/6
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PCR polymerase chain reaction
QEESI quick environmental exposure and sensitivity
inventory
RFLP restriction fragment length polymorphism
SNP single nucleotide polymorphism
SPSS Statistical Package for the Social Sciences
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